Caspase-9 drives doxorubicin-induced inflammatory cell death, PANoptosis
The Journal of Immunology · 02.11.2026 · 215 (11)
DOI: 10.1093/jimmun/vkag300 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, online erschienen am 16.11.2026. Verfasst von R K Subbarao Malireddi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN, United States. Hauptthemen laut MEDLINE: Doxorubicin, Macrophages, Caspase 9, Inflammation. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: US National Institutes of Health, the American Lebanese Syrian Associated Charities, NIH HHS.
Abstract (Originalsprache)
The anthracycline chemotherapeutic drug doxorubicin and the well-known compound staurosporine (STS) have long been regarded as prototypical inducers of the nonlytic cell death pathway apoptosis, with doxorubicin serving as a standard experimental tool for studying caspase-9–dependent intrinsic apoptosis. We recently showed that STS induces PANoptosis, a distinct lytic cell death pathway initiated by innate immune sensors and driven by caspases and/or RIPKs through PANoptosome complexes. Here, we asked whether doxorubicin similarly induces lytic cell death. Using CRISPR-Cas9 technology, we developed caspase-9–deficient immortalized bone marrow–derived macrophages to circumvent the embryonic lethality associated with germline deletion of caspase-9. We found that doxorubicin induced dose- and time-dependent lytic cell death—PANoptosis—in a caspase-9–dependent manner. Together with our previous findings on STS and caspase-8, these data demonstrate that classical inducers of nonlytic apoptosis also drive lytic, inflammatory cell death (PANoptosis) in innate immune cells, specifically macrophages. We further show that caspase-9 is a key driver of PANoptosis in response to doxorubicin and is required for the activation of caspase-1, caspase-8, caspase-3/-7, and gasdermin E, which are hallmarks of PANoptosis. These findings establish a role for caspase-9 beyond canonical apoptosis and suggest that PANoptosis and the downstream inflammatory response may contribute to the biological effects previously attributed to apoptosis for doxorubicin as a chemotherapeutic agent and for caspase-9 in other cancer and inflammatory disease settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN, United States.
ORCID-Profile: Thirumala-Devi Kanneganti
Förderung
- US National Institutes of Health
- the American Lebanese Syrian Associated Charities
- NIH HHS
- National Institutes of Health
Zitieren
APA
Malireddi, R. K. S., Sharma, B. R., Chadchan, S. B., Chen, W., Tweedell, R. E., & Kanneganti, T. D. (2026). Caspase-9 drives doxorubicin-induced inflammatory cell death, PANoptosis. The Journal of Immunology, 215(11). https://doi.org/10.1093/jimmun/vkag300
Vancouver
Malireddi RKS, Sharma BR, Chadchan SB, Chen W, Tweedell RE, Kanneganti TD. Caspase-9 drives doxorubicin-induced inflammatory cell death, PANoptosis. The Journal of Immunology. 2026;215(11). doi:10.1093/jimmun/vkag300
BibTeX
@article{Malireddi2026,
author = {Malireddi, R K Subbarao and Sharma, Bhesh Raj and Chadchan, Sangappa B and Chen, Wen and Tweedell, Rebecca E and Kanneganti, Thirumala-Devi},
title = {Caspase-9 drives doxorubicin-induced inflammatory cell death, PANoptosis},
journal = {The Journal of Immunology},
year = {2026},
volume = {215},
number = {11},
doi = {10.1093/jimmun/vkag300}
}
EUVIMED